Antibody treatment for liver graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a medicine called an anti-CD25 antibody for people who have chronic graft-versus-host disease affecting the liver and whose condition did not improve with steroids. The treatment aims to calm the immune system and may help reduce liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 65 years old.
- You had a stem cell transplant from a donor.
- You developed chronic graft-versus-host disease in your liver after the transplant.
- Your liver condition did not improve after taking prednisone (a steroid).
- You have not received more than 4 previous treatments for this condition.
- You agree to receive the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
This trial tests a combination of two medications (belumosudil and ruxolitinib) for people with chronic graft-versus-host disease (cGvHD) that has not improved with steroid treatment. The goal is to see if this combination can better control the condition.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This trial tests whether an antibody called anti-CD25 can help prevent a serious side effect (graft-versus-host disease) in adults getting a stem cell transplant for blood disorders. It is for people considered high-risk based on a special scoring model.
This study is testing whether giving a special antibody (anti-CD25) before a half-matched stem cell transplant can prevent a common side effect called graft-versus-host disease (GVHD), where donor cells attack your body. It is for people with blood cancers who are getting this type of transplant.
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.